Table 2 Multivariate logistic regression model of predisposition to cutaneous NVP HSR, according to ancestry.

From: Shared peptide binding of HLA Class I and II alleles associate with cutaneous nevirapine hypersensitivity and identify novel risk alleles

 

ALL OR [95% CI]

Caucasian OR [95% CI]

Asian OR [95% CI]

African OR [95% CI]

HLA-C*04:01

4.06 [2.39–6.88]

3.14 [1.49–6.62]

7.30 [2.74–19.5]

5.60 [1.22–25.75]

Other risk F pocket (DNKLYLRNFYWTKW) HLA-C*04:(03/06/07), -C*05:(01/09), -C*18:01

2.91 [1.62–5.23]

3.92 [1.74–8.86]

1.64 [0.53–5.12]

3.18 [0.53–19.04]

Risk B07 alleles HLA-B*35:05, -B*39:10, -B*51:(01/02), -B*54:01, HLA-B*55:(01/02), -B*56:(01/04), -B*67:01, HLA-B*78:01

2.32 [1.42–3.79]

2.27 [1.06–4.85]

2.19 [1.10–4.35]

2.93 [0.23–37.10]

Risk non-B07 HLA-B alleles HLA-B*13:02, B*38:(01/02), -B*39:(01/05/06/09), B*51:07

1.76 [1.02–3.02]

1.87 [0.76–4.57]

1.50 [0.72–3.12]

5.54 [0.30–101.20]

Protective HLA-B alleles HLA-B*15:(01/12/24/25/27/32/35), -B*52:01

0.18 [0.07–0.46]

0.25 [0.06–1.15]

0.18 [0.05–0.61]

 

Risk HLA-DRB1 alleles HLA-DRB1*01:(01/02/03), -DRB1*04:(04/05/08/10)

2.00 [1.23–3.24]

1.34 [0.68–2.64]

3.23 [1.40–7.43]

4.77 [0.95–24.04]

Slow CYP2B6 metabolizer

2.07 [1.12–3.82]

3.19 [1.04–9.78]

1.66 [0.64–4.32]

1.81 [0.45–7.33]

  1. All models have been adjusted for ethnicity as appropriate.
Back to article page